



5661 '99 MAY 24 AIO:19

26741 Portola Parkway
Suite 1E-520
Foothill Ranch, CA 92610

PHONE: (714) 649-0427
FAX: (714) 649-3548
E-MAIL: icpmail@aol.com
WEB ADDRESS: www.icppet.org

May 17, 1999

TO: DIRECTOR

Ruth Dean Tesar
FDA/CDR/Office of Drug Evaluation

FROM: DIRECTOR

Steven L. Wallace, Ph.D.
ICP Medical Systems

RE: CLINICAL

Vincent L. Wong, M.D.
St. Louis University School of Medicine

PETER S. CONTI, M.D., Ph.D.
UCLA School of Medicine and Pharmacy
Peter S. Conti, M.D., Ph.D.
UCLA School of Medicine and Pharmacy

Joseph R. Berman, Ph.D.
UCLA School of Medicine

R. Edward Coleman, M.D.
Duke University Medical Center

Samuel G. Glick, M.D., Ph.D.
UCLA School of Medicine

Kathy Hunter, CNMT
University of Tennessee Medical Center

Michael E. Phelps, Ph.D.
UCLA School of Medicine

Marvin Sandler, M.D.
Vanderbilt University

Paul Shimizu, M.D.
University of Michigan Medical Center

Conrad S. Young, D.D.
Akerside Medical Center of Illinois

PETER F. VOLK, M.D.
Northern California PET Imaging Center

JENNIFER S. KEPPLER
Jennifer S. Keppler

Ms. Jane A. Axelrad
Associate Director for Policy
Center for Drug Evaluation and Research
Food and Drug Administration
Rockville MD, 20857

Dear Ms. Axelrad:

Attached are the community's comments on the ANDA template for FDG. As you can see, our comments are minor and reflect overall support for this approach. Your group has done a tremendous job in organizing the information in a very logical format.

We look forward to continued success as we broach the remaining regulatory issues.

Respectfully,

A handwritten signature in black ink, appearing to read "Jennifer S. Keppler".
Jennifer S. Keppler
Executive Director, ICP

c. J Barrio

98D-0266

C4



Recommendations for the ANDA Template

Section 1, page 2: Change "component" to "Drug Product" and "active ingredient" to "Drug Substance"

Section 2, Part A: "Critical Components" should be identified and defined. We recommend that they be O-18 and mannose triflate

Section 2, Part A, #4, page 2: In the table, change "infra-red" to "Spectroscopy (UV-VIS, IR, NMR)" and "TLC" to "Chromatography (TLC, HPLC, GC)"

Section 2, Part B, Section II, page 4: The information in the table should be provided regardless if it is an internal source or external source of F-18 production.

Section 2D (page 5) and 5A (page 7): Combine them into a single table.

Section 5, page 7 and 8: Start out this section with Part B—makes more sense logistically.

Section 5, Part B, page 7. Clarify that this only needs to be filled out if cyclotron is in-house.

Section 5, part B, subpart iii, page 8, refers to "foils" —this is confusing because some people think of foils as the part that strip electrons in negative ion cyclotrons. Replace with "target windows".

Section 5, part B, subpart iii, page 9—remove reference to replacement of foils; it is not based on cycles

Section 5, part C, subpart iii, page 9 – clarify the bullet "control of the amount of reactants, reagents..." There seems to be no answer required.

Section 8, part B, page 11 –change acceptance criteria to "the radionuclide's gamma spectrum contains photopeaks at 0.511MeV and possibly at 1.022 MeV;" (add possibly)

Section 8 part B, page 12 Section on "Residual Solvents": recommend that this parameter be validated then confirmed every 10th batch.

Section 8 part B, page 12, Section on Sterility Testing: Recommend that this be done on an agreed upon schedule with FDA, not immediately after preparation

Section 10, page 13 part on Microbiological Validation, should contain reference to how many batches, etc would be required for microbiological validation

Section 8, part B page 12: Delete reference to pH as the USP does not specify pH limits

Section 8, part B page 12: Refer to manufacturer's specifications for limitation on membrane filter bubble point test

Section 8, part B page 12: Sterility testing – should enable the starting sterility tests the day after production due to radiation safety considerations